Rezolute, Inc. announced granting equity awards to two new employees to treat hypoglycemia caused by hyperinsulinism. The options to purchase 245,000 shares of Rezolute common stock have a 10-year term with an exercise price of $9.32 per share, vesting over four years. The company’s forward-looking statements emphasize a focus on prospective performance and strategies, with updates to be provided in accordance with SEC regulations. For more information, contact Christen Baglaneas at [email protected] or Carrie McKim at [email protected].

Read more at GlobeNewswire: Rezolute Announces Inducement Grant Under Nasdaq Listing